US HB8877 | 2021-2022 | 117th Congress
Status
Spectrum: Bipartisan Bill
Status: Introduced on September 19 2022 - 25% progression, died in committee
Action: 2022-09-20 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on September 19 2022 - 25% progression, died in committee
Action: 2022-09-20 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]
Summary
To direct the Secretary of Health and Human Services to evaluate the extent to which the substitution of interchangeable biological products may be impeded by differences between the system for determining a biological product to be interchangeable and the system for assigning therapeutic equivalence ratings to drugs, and for other purposes.
Title
Biologics Competition Act of 2022
Sponsors
| Rep. Mariannette Miller-Meeks [R-IA] | Rep. Greg Murphy [R-NC] | Rep. Nanette Barragan [D-CA] | Rep. Ann Kuster [D-NH] |
| Rep. Stephanie Bice [R-OK] |
History
| Date | Chamber | Action |
|---|---|---|
| 2022-09-20 | House | Referred to the Subcommittee on Health. |
| 2022-09-19 | House | Referred to the House Committee on Energy and Commerce. |
| 2022-09-19 | House | Introduced in House |
Subjects
US Congress State Sources
| Type | Source |
|---|---|
| Summary | https://www.congress.gov/bill/117th-congress/house-bill/8877/all-info |
| Text | https://www.congress.gov/117/bills/hr8877/BILLS-117hr8877ih.pdf |
